Trial · NCT02247375
Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)
NCT02247375, Phase 1, Completed, Boehringer Ingelheim
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA). Trials, record NCT02247375. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02247375
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)
- NCT number
- NCT02247375
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 26 participants, actual
- Lead sponsor
- Boehringer Ingelheim
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Low dose of BIIL 284 BS tablets, High dose of BIIL 284 BS tablets, Placebo
- First posted
- 2014-09-25
- Last updated
- 2014-09-25
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes from baseline in Mac-1 expression | Pre-dose, up to day 14 after start of treatment | |
| Primary | Plasma concentrations of BIIL 284 BS, BIIL 260 BS, BIIL 315 ZW and BIIL 304 ZW | Pre-dose, up to day 14 after start of treatment | |
| Primary | Maximum concentration of the analyte in plasma (Cmax) | Pre-dose, up to day 14 after start of treatment | |
| Primary | Trough concentration of the analyte in plasma shortly before drug administration in a steady state dosing interval (Cpre,ss) | Pre-dose, up to day 14 after start of treatment | |
| Primary | Time to reach the maximum concentration of the analyte in plasma (tmax) | Pre-dose, up to day 14 after start of treatment | |
| Primary | Area under the concentration-time curve of the analyte in plasma (AUC) | Pre-dose, up to day 14 after start of treatment | |
| Primary | Number of patients with adverse events | Up to 4 weeks | |
| Primary | Global assessment of tolerability by the patient on a 4-point scale | Up to 14 days after start of treatment | |
| Primary | Global assessment of tolerability by investigator on a 4-point scale | Up to 14 days after start of treatment | |
| Secondary | Changes from baseline in tender joint count (TJC) | Pre-dose, up to day 14 after start of treatment | Bilateral assessment of twenty-eight joints by e.g., pressure, joint manipulation etc. |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02247375
GET https://conductscience.org/api/trials/v1/NCT02247375/registered?page=2